Resources from the same session
1257O - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: David Hong
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1258O - Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
Presenter: Byoung Chul Cho
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Presenter: Li Zhang
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1259O - A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)
Presenter: Yukihiro Toi
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Lecia Sequist
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Webcast
Invited Discussant LBA50 and 1259O
Presenter: Lecia Sequist
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Webcast
Q&A and live discussion
Presenter: Lecia Sequist
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Webcast